Clinical observation of bevacizumab combined with paclitaxel and carboplatin chemotherapy in the treatment of persistent or recurrent cervical cancer
- VernacularTitle:贝伐珠单抗联合紫杉醇+卡铂治疗持续性或复发性宫颈癌的临床观察
- Author:
Liyi ZHANG
1
;
Fengxi JIANG
1
;
Dingqing GUI
1
Author Information
1. Dept. of Gynaecology and Obstetrics，Dazhou Central Hospital，Sichuan Dazhou 635000，China
- Publication Type:Journal Article
- Keywords:
persistent cervical cancer;
recurrent cervical cancer;
bevacizumab;
paclitaxel;
carboplatin;
therapeutic efficacy
- From:
China Pharmacy
2024;35(17):2126-2130
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To explore the short-term and long-term efficacy of bevacizumab combined with paclitaxel （PTX） and carboplatin （CBP） chemotherapy in the treatment of persistent or recurrent cervical cancer， as well as its impact on patient quality of life， tumor markers and safety. METHODS Totally 80 patients with persistent or recurrent cervical cancer admitted to our hospital from January 2020 to October 2022 were randomly divided into control group （40 cases） and observation group （40 cases） using a random number table method. Both groups received PTX+CBP chemotherapy， while the observation group was treated with bevacizumab in combination. Both groups were treated continuously for 6 cycles. The recent efficacy， the incidence of toxic side effects as well as European Organization for Research and Treatment of Cancer Life Questionnaire Core 30 （EORTC QLQ-C30） scores， and the serum tumor markers [carcinoembryonic antigen （CEA）， carbohydrate antigen 125 （CA125）， and squamous cell carcinoma antigen （SCCA）] levels before and at the end of the entire course of treatment were compared between two groups. The survival curves of the two groups were drawn by using Kaplan-Meier method， and progression-free survival （PFS） and overall survival （OS） were compared between the two groups by Log-rank test. RESULTS The objective response rate of the observation group was significantly higher than that of the control group （62.50% vs. 35.00%， P＜0.05）， and the median PFS （9.30 months vs. 6.30 months） and median OS （14.90 months vs. 10.60 months） were also significantly longer than the control group （P＜0.05）. EORTC QLQ-C30 score of the observation group after treatment was significantly higher than that of the control group （P＜0.05）. Compared to before treatment， the serum levels of CEA， CA125 and SCCA in both groups were significantly reduced after treatment （P＜0.05）， while the observation group had a larger decrease （P＜0.05）. There was no significant difference in the grading of various types of toxic side effects between the two groups during treatment （P＞0.05）. Most patients experienced automatic disappearance of toxic side effects 1-2 months after discontinuation of medication， or symptoms disappearance after symptomatic treatment. CONCLUSIONS The combination of bevacizumab and PTX+CBP chemotherapy regimen can effectively improve the objective efficacy rate of persistent or recurrent cervical cancer， reduce serum tumor marker levels， improve patient quality of life， prolong survival， and have good safety.
